Description

Clinical Evidence

• A landmark study in Acta Physiologica Scandinavica (1977) demonstrated DSIP’s ability to induce delta sleep when administered intracerebroventricularly in rabbits.
• DSIP has been shown to reduce stress-induced increases in ACTH and cortisol in rodent models (Peptides, 1986).
• In models of ischemic brain injury, DSIP exhibited anti-apoptotic and anti-inflammatory effects, suggesting potential neuroprotective roles.
• Some clinical experiments have noted improved sleep and reduced anxiety symptoms in small human cohorts, though findings remain preliminary.
• DSIP’s wide-ranging actions across endocrine, neural, and metabolic pathways make it a versatile candidate for ongoing peptide research.

Potential Side Effects

DSIP has shown low toxicity and high tolerability in both animal and limited human studies. However, possible effects in research contexts include:

• Mild sedation or drowsiness
• Temporary changes in sleep cycles or vivid dreaming
• Hypotension (rare and dose-dependent)
• Headache or mild cognitive dulling (transient)
• These effects are typically short-lived and dose-sensitive. DSIP does not appear to build dependence or tolerance in observed

Disclaimer

DSIP is for laboratory research use only. It is not approved for human consumption or therapeutic use. All data presented reflect findings from preclinical studies and exploratory human research. Use by qualified personnel in controlled laboratory environments only.